IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions
Univar Solutions' pharmaceutical ingredients portfolio will be strengthened by the addition of a broad range of cellulose ethers and other excipient solutions
Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
The special financing terms offered by United Imaging and structured by Medikabazaar to Krsnaa Diagnostics underscore the strategic importance of this alliance
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
Focus on consolidation could help them strengthen their position in the competitive pharmaceutical industry, potentially driving expansion and improving efficiencies
Agreement further expands Aptar Pharma’s leading respiratory portfolio
ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the USFDA
Subscribe To Our Newsletter & Stay Updated
